Abraxane For Stage â…£ Non-small Cell Lung Cancer Failure To Multi-line Chemotherapy

Object To evaluate the clinical efficacy and safety of abraxane in treating the failure previously of stage â…£ non-small cell lung cancer(NSCLC).Methods Retrospective analysis of 28 cases of stage â…£ NSCLC who had progressed from at least one standard anti-tumor chemotherapy and then followed by monotherapy of abraxane at 130mg/m2 every three weeks on day1, day 8. We assessed the short-term effecacy and safety as well as treatment associated progress free survival(PFS) for these patients, and meanwhile, preliminary analysis of pathological type and age were carried out.Results Among the 28 patients, CR was 0(0%), PR was 6(21.4%), SD was 13(46.4%), PD was 9(32.1%), the ORR was 21.4%, and the disease control rate(DCR) was 67.9%, the PFS was 4.2 months(95% CI: 2.8-6.5 months). The main grade 3 of sideffects were neutropenia(17.9%), peripheral nerve damage(3.57%), thrombocytopenia(3.57%), only 1 patient developed stage IV bone marrow suppression. The ORR in the squamous lung cancer vs. non-squamous NSCLC was 23.1% vs 20%(P=0.843), and the PFS was 4.6 vs. 4.2 months(P=0.433). Among the elderly patients, the ORR and DCR was 22.2% and 66.7% respectively with a good therapeutic effect and tolerance.Conclusion Abraxane shows a good efficacy in the treatment of previously treated stage â…£ NSCLC and well tolerated. Investigation of abraxane in larger samples is worthy due to its prominent therapeutic effect in squamous lung cancer and elder patients.